Epidemiology and Mechanisms of Ceftazidime–Avibactam Resistance in Gram-Negative Bacteria
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Epidemiology and Mechanisms of Ceftazidime–Avibactam Resistance in Gram-Negative Bacteria
Authors
Keywords
Ceftazidime–avibactam, Resistance mechanism, Carbapenem-resistant, β-lactam/β-lactamase inhibitor
Journal
Engineering
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-01-22
DOI
10.1016/j.eng.2020.11.004
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- In Vitro Activity of Ceftazidime-Avibactam Against Isolates from Respiratory and Blood Specimens from Patients with Nosocomial Pneumonia, including Ventilator-Associated Pneumonia, in a Phase 3 Clinical Trial
- (2020) Gregory G. Stone et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Detection in two hospitals of transferable ceftazidime-avibactam resistance in Klebsiella pneumoniae due to a novel VEB β-lactamase variant with a Lys234Arg substitution, Greece, 2019
- (2020) E. Voulgari et al. Eurosurveillance
- Outbreak of KPC-2-producing Klebsiella pneumoniae endowed with ceftazidime-avibactam resistance mediated through a VEB-1-mutant (VEB-25), Greece, September to October 2019
- (2020) Irene Galani et al. Eurosurveillance
- KPC-50 confers resistance to ceftazidime-avibactam associated with reduced carbapenemase activity
- (2020) Laurent Poirel et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftazidime-Avibactam Resistance Mediated by the N346Y Substitution in Various AmpC β-Lactamases
- (2020) Fabrice Compain et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Emergence of ceftazidime/avibactam resistance in KPC-8–producing Klebsiella pneumoniae in South America
- (2020) J. García et al. CLINICAL MICROBIOLOGY AND INFECTION
- Bloodstream infection by two subpopulations of Klebsiella pneumoniae ST1685 carrying KPC-33 or KPC-14 following ceftazidime/avibactam treatment: considerations regarding acquired heteroresistance and choice of carbapenemase detection assay
- (2020) Gabriele Bianco et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Emergence of Hypervirulent Ceftazidime/Avibactam-Resistant Klebsiella pneumoniae Isolates in a Chinese Tertiary Hospital
- (2020) Dan Li et al. Infection and Drug Resistance
- In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against Pseudomonas aeruginosa isolated from patients with cystic fibrosis
- (2020) Patrick J. Nolan et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- A Ceftazidime-Avibactam-Resistant and Carbapenem-Susceptible Klebsiella pneumoniae Strain Harboring blaKPC-14 Isolated in New York City
- (2020) Siqiang Niu et al. mSphere
- In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa: Results from a Multicenter Study in China, 2017
- (2019) Dandan Yin et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens
- (2019) Ilias Karaiskos et al. Expert Opinion on Drug Metabolism & Toxicology
- OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs
- (2019) Christopher Fröhlich et al. mSphere
- Interplay between β-lactamases and new β-lactamase inhibitors
- (2019) Karen Bush et al. NATURE REVIEWS MICROBIOLOGY
- Ceftazidime/avibactam resistance associated with L169P mutation in the omega loop of KPC-2
- (2019) Peera Hemarajata et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients
- (2019) Roxana Zamudio et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015
- (2019) James A. Karlowsky et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam
- (2019) Matthaios Papadimitriou-Olivgeris et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Unravelling ceftazidime/avibactam resistance of KPC-28, a KPC-2 variant lacking carbapenemase activity
- (2019) Saoussen Oueslati et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo
- (2019) Stephan Göttig et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Longitudinal analysis of the in vitro activity of ceftazidime-avibactam vs. Enterobacteriaceae, 2012-2016
- (2019) Elmano Ramalheira et al. Journal of Global Antimicrobial Resistance
- Phenotypic, biochemical and genetic analysis of KPC-41, a KPC-3 variant conferring resistance to ceftazidime-avibactam and exhibiting reduced carbapenemase activity
- (2019) Linda Mueller et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China
- (2019) P. Zhang et al. CLINICAL MICROBIOLOGY AND INFECTION
- Combination of amino acid substitutions leading to CTX-M-15-mediated resistance to the ceftazidime-avibactam combination
- (2018) Fabrice Compain et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clonal background, resistance gene profile, and porin gene mutations modulate in vitro susceptibility to imipenem/relebactam in diverse Enterobacteriaceae
- (2018) Angela Gomez-Simmonds et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment
- (2018) Paolo Gaibani et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial
- (2018) Antoni Torres et al. LANCET INFECTIOUS DISEASES
- Activity of Ceftazidime–Avibactam Against Clinical Isolates of Klebsiella pneumoniae, Including KPC-Carrying Isolates, Endemic to New York City
- (2018) Nyla Manning et al. Microbial Drug Resistance
- Loss of activity of ceftazidime-avibactam due to Mex-AB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis
- (2018) Hussein Chalhoub et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime–avibactam
- (2018) Stan Atkin et al. Infection and Drug Resistance
- Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-Resistant Klebsiella pneumoniae Bacteremia and Abscess in a Liver Transplant Recipient
- (2018) Vasilios Athans et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Emergence of ceftazidime/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate
- (2017) Anna Both et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- High ceftazidime hydrolysis activity and porin OmpK35 deficiency contribute to the decreased susceptibility to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae
- (2017) Zhen Shen et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Klebsiella pneumoniae Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering
- (2017) Melissa D. Barnes et al. mBio
- In VitroSusceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014)
- (2016) Wright W. Nichols et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Identification of Novel VEB β-Lactamase Enzymes and Their Impact on Avibactam Inhibition
- (2016) Sushmita D. Lahiri et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Low Frequency of Ceftazidime-Avibactam Resistance among Enterobacteriaceae Isolates Carrying bla KPC Collected in U.S. Hospitals from 2012 to 2015
- (2016) Mariana Castanheira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne bla KPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections
- (2016) Ryan K. Shields et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production inEnterobacteriaceaeBloodstream Infections at a Major Cancer Center: Table 1.
- (2016) Samuel L. Aitken et al. CLINICAL INFECTIOUS DISEASES
- Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program
- (2016) John E. Mazuski et al. CLINICAL INFECTIOUS DISEASES
- Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.
- (2016) Ryan K. Shields et al. CLINICAL INFECTIOUS DISEASES
- B1-Metallo-β-Lactamases: Where Do We Stand?
- (2016) Maria F. Mojica et al. CURRENT DRUG TARGETS
- Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis
- (2016) Oren Zusman et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae
- (2016) Joshua T. Thaden et al. Virulence
- First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate
- (2015) Romney M. Humphries et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effects of Klebsiella pneumoniae Carbapenemase Subtypes, Extended-Spectrum β-Lactamases, and Porin Mutations on theIn VitroActivity of Ceftazidime-Avibactam against Carbapenem-Resistant K. pneumoniae
- (2015) Ryan K. Shields et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroSelection of Ceftazidime-Avibactam Resistance in Enterobacteriaceae with KPC-3 Carbapenemase
- (2015) David M. Livermore et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of ceftazidime/avibactam against isogenic strains ofEscherichia colicontaining KPC and SHV β-lactamases with single amino acid substitutions in the Ω-loop
- (2015) Marisa L. Winkler et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Avibactam confers susceptibility to a large proportion of ceftazidime-resistantPseudomonas aeruginosaisolates recovered from cystic fibrosis patients
- (2015) Hussein Chalhoub et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases
- (2015) Scott J. Hecker et al. JOURNAL OF MEDICINAL CHEMISTRY
- In VitroSusceptibility of Characterized β-Lactamase-Producing Strains Tested with Avibactam Combinations
- (2014) Henry Li et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Unexpected Challenges in Treating Multidrug-Resistant Gram-Negative Bacteria: Resistance to Ceftazidime-Avibactam in Archived Isolates of Pseudomonas aeruginosa
- (2014) Marisa L. Winkler et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Combination therapy for carbapenem-resistant Gram-negative bacteria
- (2014) M. Paul et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- New β-Lactamase Inhibitors: a Therapeutic Renaissance in an MDR World
- (2013) Sarah M. Drawz et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Organisms Collected from U.S. Medical Centers in 2012
- (2013) Helio S. Sader et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination
- (2013) George G. Zhanel et al. DRUGS
- Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases
- (2013) David E. Ehmann et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Exploring the Role of a Conserved Class A Residue in the Ω-Loop of KPC-2 β-Lactamase
- (2012) Peter S. Levitt et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Avibactam is a covalent, reversible, non- -lactam -lactamase inhibitor
- (2012) D. E. Ehmann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors
- (2011) Ken Coleman CURRENT OPINION IN MICROBIOLOGY
- Epidemiological Expansion, Structural Studies, and Clinical Challenges of New β-Lactamases from Gram-Negative Bacteria
- (2010) Karen Bush et al. Annual Review of Microbiology
- Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-ProducingEnterobacteriaceae
- (2010) David M. Livermore et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Multidrug-Resistant Gram-Negative Infections
- (2009) Helen Giamarellou et al. DRUGS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started